There’s a lot to be optimistic about in the Healthcare sector as 3 analysts just weighed in on Sophiris Bio (NASDAQ:SPHS), Soleno Therapeutics Inc (NASDAQ:SLNO) and Petiq Inc (NASDAQ:PETQ) with bullish sentiments.
Sophiris Bio (SPHS)
Maxim Group analyst Jason McCarthy maintained a Buy rating on Sophiris Bio today and set a price target of $8. The company’s shares closed yesterday at $2.74.
McCarthy said:
“Sophiris reported 2Q18 with a net loss of ($6.1M) and ended the period with $18.5M in cash on the balance sheet, sufficient runway into 1H19. The next event for Sophiris is in 4Q18 when additional readouts (second dose data) of the P2b study of topsalysin in localized prostate cancer (PC) are reported.”
According to TipRanks.com, McCarthy is a 5-star analyst with an average return of 12.0% and a 44.3% success rate. McCarthy covers the Healthcare sector, focusing on stocks such as SELLAS Life Sciences Group Inc, ContraVir Pharmaceuticals Inc, and Sonoma Pharmaceuticals Inc.
The word on The Street in general, suggests a Strong Buy analyst consensus rating for Sophiris Bio with a $6.43 average price target, implying a 134.5% upside from current levels. In a report released today, H.C. Wainwright also maintained a Buy rating on the stock with a $4.30 price target.
.
See today’s analyst top recommended stocks >>
Soleno Therapeutics Inc (SLNO)
Maxim Group analyst Caroline Palomeque maintained a Buy rating on Soleno Therapeutics Inc today and set a price target of $4. The company’s shares closed yesterday at $2.66.
Palomeque observed:
“Soleno reported 2Q18 with a net loss of ($7.6M), having spent $3.4M in operating expenses to end the period with $12.6M in cash, sufficient runway into mid-19 and likely to the completion of the ongoing pivotal study of DCCR (diazoxide choline controlled-release tablets) in Prader-Willi syndrome (PWS).”
According to TipRanks.com, Palomeque is currently ranked with no stars on a 0-5 star ranking scale, with an average return of -8.4% and a 32.7% success rate. Palomeque covers the Healthcare sector, focusing on stocks such as VistaGen Therapeutics, Anavex Life Sciences, and Neurotrope.
The word on The Street in general, suggests a Moderate Buy analyst consensus rating for Soleno Therapeutics Inc with a $9 average price target.
Petiq Inc (PETQ)
In a report released today, Brian Nagel from Oppenheimer maintained a Buy rating on Petiq Inc. The company’s shares closed yesterday at $28.28, close to its 52-week high of $29.55.
According to TipRanks.com, Nagel is a 5-star analyst with an average return of 8.4% and a 65.7% success rate. Nagel covers the Services sector, focusing on stocks such as Restoration Hardware Holdings Inc, Dick’s Sporting Goods, and Advance Auto Parts.
Petiq Inc has an analyst consensus of Strong Buy, with a price target consensus of $27, a -4.5% downside from current levels. In a report issued on August 9, Jefferies also maintained a Buy rating on the stock.
.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
